Medifast MED Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $76.04M-34.3% | $75.1M-36.9% | $89.41M-36.2% | $105.56M-37.4% | $115.73M-33.8% | ||
| $24.29M-22.9% | $22.96M-25.4% | $27.25M-21.0% | $28.91M-35.9% | $31.48M-33.6% | ||
| $51.76M-38.6% | $52.14M-40.9% | $62.16M-41.2% | $76.64M-37.9% | $84.25M-33.8% | ||
| 68.1%-4.7pp | 69.4%-4.7pp | 69.5%-5.9pp | 72.6%-0.6pp | 72.8%-0.1pp | ||
| $55.05M-35.6% | $59.94M-31.5% | $66.24M-36.0% | $77.71M-40.8% | $85.51M-28.4% | ||
| $3.48M+6.2% | $3.47M+8.8% | $3.45M+8.1% | $4.05M+31.9% | $3.28M+0.6% | ||
| -$3.3M-161% | -$7.8M-1,201% | -$4.08M-294% | -$1.07M+86.5% | -$1.26M-116% | ||
| -4.3%-3.2pp | -10.4%-11.0pp | -4.6%-6.1pp | -1%+3.7pp | -1.1%-5.6pp | ||
| $1.38M+6.0% | —— | $1.43M+7.0% | $1.37M+5.6% | $1.3M+6.4% | ||
| $1.35M-24.3% | $1.42M+151% | $1.42M+370% | $3.94M+242% | $1.79M-50.9% | ||
| -$1.94M-469% | -$6.38M-601% | -$2.66M-268% | $2.88M+127% | $526K-95.5% | ||
| $181K-86.1% | $11.74M+2,376% | -$396K-188% | $395K+116% | $1.3M-60.3% | ||
| -$2.12M-175% | -$18.12M-2,362% | -$2.26M-300% | $2.48M+130% | -$772K-109% | ||
| -2.8%-2.1pp | -24.1%-24.8pp | -2.5%-3.3pp | 2.3%+7.2pp | -0.7%-5.4pp | ||
| -$0.19-171% | -$1.65-2,457% | -$0.21-310% | $0.22+129% | -$0.07-109% | ||
| -$0.19-171% | -$1.65-2,457% | -$0.21-310% | $0.23+131% | -$0.07-109% | ||
| 11M+0.5% | 11M+0.2% | 11M+0.2% | 11.1M+1.1% | 10.9M-0.1% | ||
| 11M+0.5% | 11M+0.5% | 11M+0.5% | 11M+0.5% | 10.9M+0.4% | ||
| -$66K-111% | $3K+101% | $14K+101% | -$620K+85.2% | $620K-74.6% | ||
| $0-100% | $12.11M+261% | -$648K-711% | -$20K+80.6% | $20K-82.1% | ||
| -$63K+83.7% | -$372K-879% | -$606K— | -$8K+78.9% | -$387K-2,877% | ||
| $241K-91.7% | —— | —— | —— | $2.91M+3,014% | ||
| -$1.45M+75.8% | -$4.3M+61.6% | -$516K+88.1% | -$13.1M-273% | -$6M+62.3% | ||
| -$200K-118% | -$816K-108% | $0-100% | -$7.14M-119% | $1.14M-65.0% | ||
| $1.18M+138% | -$2.98M— | -$7M— | -$9.16M-37.4% | -$3.06M+63.2% | ||
| -$262K-739% | $1.89M+512% | $0-100% | $267K+247% | $41K+271% | ||
| -$649K-789% | —— | -$2.23M+61.4% | -$512K-148% | -$73K-110% | ||
| -$901K-60.0% | —— | —— | -$2K+90.0% | -$563K+62.2% | ||
| -$17.13M-734% | -$4.95M+74.5% | -$14.28M-701% | $13.36M+628% | -$2.05M+26.0% | ||
| $260K-92.4% | —— | $12.11M+33.5% | —— | $3.41M-53.2% | ||
| -$25K-105% | $1K+100% | -$2K+99.9% | $2.57M+163% | $487K-79.9% | ||
| $87K-55.2% | —— | —— | $1K-75.0% | $194K-72.7% | ||
| $49.32M+229% | $32.91M+48.0% | $20.43M+205% | $16.07M+89.6% | $14.99M+63.5% | ||
| $1.1M-28.0% | $1.35M-40.9% | $1.36M-1.9% | $1.38M-28.9% | $1.52M-17.3% | ||
| $29.65M+105% | $29.31M+475% | $7.52M+19.0% | $30.81M+291% | $14.46M+75.6% | ||
| $76.04M-34.3% | $75.1M-36.9% | $89.41M-36.2% | $105.56M-37.4% | $115.73M-33.8% | ||
| $1.9M-1.8% | $2.17M+1.9% | $910K+50.2% | $2.63M+7.0% | $1.93M-11.1% | ||
| -$3.3M-161% | -$7.8M-1,201% | -$4.08M-294% | -$1.07M+86.5% | -$1.26M-116% | ||
| $188K-90.7% | -$4.34M-211% | -$629K-112% | $2.98M+162% | $2.02M-82.0% | ||
| $188K-90.7% | -$4.34M-211% | -$629K-112% | $2.98M+162% | $2.02M-82.0% | ||
| 0.2%-1.5pp | -5.8%-9.0pp | -0.7%-4.5pp | 2.8%+5.7pp | 1.7%-4.7pp | ||
| -$3.3M-161% | -$7.8M-1,201% | -$4.08M-294% | -$1.07M+86.5% | -$1.26M-116% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Medifast's revenue?
- Medifast (MED) generated $346.1M in revenue over the trailing twelve months, down 36.3% year over year.
- Is Medifast profitable?
- Medifast is not currently profitable: it reported a net loss of $20.0M over the trailing twelve months, a -5.8% net margin.
- What are Medifast's profit margins?
- Gross margin is 70.1% and operating margin is -4.7%, with a -5.8% net margin.
- What is Medifast's earnings per share?
- Medifast's diluted EPS over the trailing twelve months is $-1.83.
- Where does Medifast's income statement data come from?
- Every line is extracted from Medifast's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
